Literature DB >> 18036872

Pars planitis: a 20-year study of incidence, clinical features, and outcomes.

Mark J Donaldson1, Jose S Pulido, David C Herman, Nancy Diehl, David Hodge.   

Abstract

PURPOSE: To measure the incidence of pars planitis in a community-based population and to report clinical features, complications, and visual prognosis.
DESIGN: Population-based, retrospective, 20-year cohort study.
METHODS: Multicenter study using the Rochester Epidemiology Project medical records linkage system, which allows analysis of almost all patients within Olmsted County, Minnesota, with a given medical condition. Databases were searched to identify all patients with pars planitis from January 1, 1985 through December 31, 2004. Forty-six eyes of 25 patients were evaluated.
RESULTS: Mean follow-up was 14.3 years. The incidence of pars planitis was 2.077 per 100,000 persons (95% confidence interval [CI], 1.43 to 2.62). The most common complications were epiretinal membrane (ERM) in 17 eyes (36%), cataract in 14 eyes (30.4%), and cystoid macular edema (CME) in 12 eyes (26.1%). Mean visual acuity after 10 years of follow-up was 20/30, with 18 of 24 patients maintaining a visual acuity of 20/40 or better. One-third of patients maintained normal visual acuity without requiring treatment.
CONCLUSIONS: The visual prognosis of pars planitis is relatively good, with 75% of patients maintaining a visual acuity of 20/40 or better after 10 years. Many patients with mild disease do not require treatment. A subset of patients, however, experience severe disease with severe vision loss despite treatment. The rate of smoking and multiple sclerosis in patients with pars planitis is much higher than that of the general population.

Entities:  

Mesh:

Year:  2007        PMID: 18036872     DOI: 10.1016/j.ajo.2007.08.023

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  48 in total

1.  Smokers with multiple sclerosis are more likely to report comorbid autoimmune diseases.

Authors:  Ruth Ann Marrie; Ralph I Horwitz; Gary Cutter; Tuula Tyry; Timothy Vollmer
Journal:  Neuroepidemiology       Date:  2011-02-01       Impact factor: 3.282

2.  Microcystic macular oedema in multiple sclerosis is associated with disease severity.

Authors:  Jeffrey M Gelfand; Rachel Nolan; Daniel M Schwartz; Jennifer Graves; Ari J Green
Journal:  Brain       Date:  2012-04-25       Impact factor: 13.501

Review 3.  Intermediate uveitis.

Authors:  B Manohar Babu; S R Rathinam
Journal:  Indian J Ophthalmol       Date:  2010 Jan-Feb       Impact factor: 1.848

4.  [Intermediate uveitis: guidelines of the German Ophthalmological Society and the Professional Association of German Ophthalmologists].

Authors:  F Mackensen; L Baydoun; J Garweg; A Heiligenhaus; T Hudde
Journal:  Ophthalmologe       Date:  2014-11       Impact factor: 1.059

5.  Outcomes of cataract surgery with/without vitrectomy in patients with pars planitis and immunosuppressive therapy.

Authors:  Tania Albavera-Giles; Juan Carlos Serna-Ojeda; Aida Jimenez-Corona; Miguel Pedroza-Seres
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-04-10       Impact factor: 3.117

6.  Multiple Sclerosis and Panuveitis: A Rare Association.

Authors:  Burcu Gökçe Çokal; H Nalan Güneş; Selda Keskin Güler; Tahir Kurtuluş Yoldaş; Caner Baydar; Sevim Kavuncu
Journal:  Noro Psikiyatr Ars       Date:  2016-03-01       Impact factor: 1.339

7.  Factors Predicting Visual Acuity Outcome in Intermediate, Posterior, and Panuveitis: The Multicenter Uveitis Steroid Treatment (MUST) Trial.

Authors:  John H Kempen; Mark L Van Natta; Michael M Altaweel; James P Dunn; Douglas A Jabs; Susan L Lightman; Jennifer E Thorne; Janet T Holbrook
Journal:  Am J Ophthalmol       Date:  2015-09-18       Impact factor: 5.258

8.  Use of Immunosuppressive Medications for Treatment of Pediatric Intermediate Uveitis.

Authors:  Aimee O Hersh; Spencer Cope; John F Bohnsack; Akbar Shakoor; Albert T Vitale
Journal:  Ocul Immunol Inflamm       Date:  2016-12-14       Impact factor: 3.070

Review 9.  [Uveitis in multiple sclerosis : Overview and perspectives].

Authors:  A L Hildebrandt; F Mackensen
Journal:  Ophthalmologe       Date:  2014-08       Impact factor: 1.059

10.  Microcystic macular oedema, thickness of the inner nuclear layer of the retina, and disease characteristics in multiple sclerosis: a retrospective study.

Authors:  Shiv Saidha; Elias S Sotirchos; Mohamed A Ibrahim; Ciprian M Crainiceanu; Jeffrey M Gelfand; Yasir J Sepah; John N Ratchford; Jiwon Oh; Michaela A Seigo; Scott D Newsome; Laura J Balcer; Elliot M Frohman; Ari J Green; Quan D Nguyen; Peter A Calabresi
Journal:  Lancet Neurol       Date:  2012-10-04       Impact factor: 44.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.